Filing Flows › BioMarin Pharmaceutical (BMRN) › Q3 2026 › vs Q3 2025
BioMarin Pharmaceutical (BMRN) Q3 2026 vs Q3 2025 (year over year)
BioMarin Pharmaceutical's revenue rose $249M (+32%) from $776M in Q3 2025 to $1.0B in Q3 2026. The biggest changes: Net product revenues +$255M (+34%); Royalty and other revenues −$3.8M (-25%).
BioMarin Pharmaceutical, Q3 2026: revenue $1.0B (+32% year over year), operating margin -8.0%, net loss $123M, operating cash flow $188M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 15.6% | 43.8% | -28.2 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| VOXZOGO | $245M | $218M | $26.6M | +12% |
| VIMIZIM | $216M | $183M | $33.0M | +18% |
| GALAFOLD | $152M | $0 | $152M | — |
| PALYNZIQ | $111M | $109M | $2.3M | +2% |
| NAGLAZYME | $108M | $122M | −$14.2M | -12% |
| ALDURAZYME | $56.6M | $53.7M | $2.9M | +5% |
| BRINEURA | $52.7M | $48.0M | $4.8M | +10% |
| POMBILITI + OPFOLDA | $48.6M | $0 | $48.6M | — |
| KUVAN | $22.9M | $24.0M | −$1.1M | -4% |
| Net product revenues | $1.0B | $758M | $255M | +34% |
| Royalty and other revenues | $11.6M | $15.3M | −$3.8M | -25% |
| Revenue | $1.0B | $776M | $249M | +32% |
| Income tax benefit | $8.9M | −$4.4M | $13.4M | — |
| Net loss | $123M | $30.7M | $92.1M | +300% |
| Costs & expenses | $1.2B | $827M | $329M | +40% |
| Operating costs | $1.1B | $823M | $284M | +35% |
| Interest & other, net | $49.7M | −$20.4M | $70.1M | — |
| Cost of revenue | $205M | $140M | $65.3M | +47% |
| Research & development | $181M | $409M | −$229M | -56% |
| SG&A | $334M | $268M | $65.2M | +24% |
| Other operating costs | $387M | $4.8M | $382M | 80× |
| Operating cash sources | $311M | $399M | −$88.4M | -22% |
| Depreciation & amortization | $130M | $18.5M | $112M | +606% |
| Share-based compensation | $53.5M | $49.3M | $4.3M | +9% |
| Working capital & other | $127M | $332M | −$205M | -62% |
| Net loss absorbed | $123M | $30.7M | $92.1M | +300% |
| Operating cash flow | $188M | $369M | −$180M | -49% |
| Free cash flow (OCF − capex) | $160M | $340M | −$180M | -53% |
| Capital expenditures | $28.3M | $28.4M | −$154K | -0.5% |
Questions
How much did BioMarin Pharmaceutical's revenue grow year over year in Q3 2026?
BioMarin Pharmaceutical's revenue rose $249M (+32%) from $776M in Q3 2025 to $1.0B in Q3 2026.
What drove BioMarin Pharmaceutical's revenue change in Q3 2026?
Net product revenues +$255M (+34%); Royalty and other revenues −$3.8M (-25%).